Jan 09, 2024 / 11:45PM GMT
Robbie Marcus JPMorgan-Analyst
Good afternoon, everyone. I'm Robbie Marcus, medtech analyst at JPMorgan. Really happy to introduce our next session. John Treace, the CEO of Treace Medical. John, I'll hand it over to you and then we'll do some Q&A.
John Treace Treace Medical Concepts - Inc. - CEO, Founder & Board Member
Right, great. Thanks. Thanks, Robbie, and good afternoon, everyone. Thanks for joining us here today. It's great to be at the JPMorgan Healthcare Conference and have the opportunity to talk about Treace Medical.
Since our IPO in 2021, we've continued to execute on our strategic plan, resulting in US growth of 32% during 2023, encouraging EBITDA progress and continued gains in our operating metrics, reaffirming once again, we have the right strategies in place to expand the market penetration of our differentiated technologies.
Safe Harbor disclosure here. Please refer to our website. Our non-GAAP reconciliations are also on the website.
So Treace Medical is a high-growth medtech company focused on
Treace Medical Concepts Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers